Skip to content
Screener

Arcus Biosciences RCUS Common Stock Par Value Per Share

Common Stock Par Value Per Share at other companies

Merck & Co. logo
Merck & Co.MRK
$0.500.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$0.000.0%
Incyte logo
IncyteINCY
$0.000.0%
CTO
Citius Oncology, Inc.CTOR
$0.000.0%
Gilead Sciences logo
Gilead SciencesGILD
$0.000.0%
Summit Therapeutics logo
Summit TherapeuticsSMMT

Other financials

Income statement

See full
Revenue$41.0M-74.4%
Operating income-$96.0M-1,100%
Net income-$91.0M
EPS (diluted)-$0.72

Balance sheet

See full
Cash & equivalents$150.0M-39.5%
Total debt$114.0M+4.6%
Total equity$464.0M-15.5%
Total assets$924.0M-14.0%

Cash flow

See full
Operating cash flow-$119.0M+10.5%
CapEx-
Free cash flow-$119.0M+10.5%

Valuation

See full
Market cap$3.61B+259%
Enterprise value$3.57B+312%
P/S30.8×+27.0×

Profitability

See full
Operating margin-415.4%-756pp
Net margin-393.2%-663pp
FCF margin-406%

Returns & leverage

See full
Return on equity-90.8%+373pp
Debt / equity0.2×0.0×
Current ratio3.8×-0.7×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001724521-26-000044
Line itemJune 30,2026December 31,2025
Other noncurrent liabilities124135
Commitments
Stockholders’ equity:
Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 127.0 shares in 2026 and 125.3 shares in 2025 issued and outstanding2,1692,116
Accumulated deficit(1,704)(1,485)
Accumulated other comprehensive loss(1)
Total stockholders’ equity464631
Total liabilities and stockholders’ equity$924$1,139

Item 1. Financial Statements

FAQ

What is Arcus Biosciences's common stock par value per share?
Arcus Biosciences (RCUS) reported common stock par value per share of $0.00 in Q2 2026.
How has Arcus Biosciences's common stock par value per share changed year-over-year?
Arcus Biosciences's common stock par value per share decreased by 0.0% year-over-year, from $0.00 to $0.00.
What is the long-term trend for Arcus Biosciences's common stock par value per share?
Over 3 years (2022 to 2025), Arcus Biosciences's common stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.00 to $0.00.
What does common stock par value per share mean?
The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.

Ask your AI about Arcus Biosciences's common stock par value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude